Role of PDLIM4 and c-Src in breast cancer progression
- Авторы: Kravchenko D.S.1,2, Frolova E.I.1, Kravchenko J.E.1,2, Chumakov S.P.1,2
-
Учреждения:
- Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
- Engelhardt Institute of Molecular Biology
- Выпуск: Том 50, № 1 (2016)
- Страницы: 59-68
- Раздел: Reviews
- URL: https://journals.rcsi.science/0026-8933/article/view/162504
- DOI: https://doi.org/10.1134/S002689331601009X
- ID: 162504
Цитировать
Аннотация
High heterogeneity is characteristic of oncology diseases, often complicating the choice of optimal anticancer treatment. One cancer type may combine tumors differing in histogenesis, genetic lesions, and mechanism of cell transformation. Differences in the mechanism of cell malignant transformation result in specifics of cancer cell metabolism and sensitivity to various agents, including anticancer treatments. Hence, the molecular subtype of a tumor is essential to know for choosing the optimal therapeutic strategy. The review considers the role actin-associated proteins and tyrosine kinases, in particular, PDLIM4 and Src kinase, play in the formation of pathological signaling pathways.
Ключевые слова
Об авторах
D. Kravchenko
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry; Engelhardt Institute of Molecular Biology
Автор, ответственный за переписку.
Email: stepan@chumakov.email
Россия, Moscow, 117997; Moscow, 117997
E. Frolova
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry
Email: stepan@chumakov.email
Россия, Moscow, 117997
J. Kravchenko
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry; Engelhardt Institute of Molecular Biology
Email: stepan@chumakov.email
Россия, Moscow, 117997; Moscow, 117997
S. Chumakov
Shemyakin–Ovchinnikov Institute of Bioorganic Chemistry; Engelhardt Institute of Molecular Biology
Email: stepan@chumakov.email
Россия, Moscow, 117997; Moscow, 117997
Дополнительные файлы
